Revolution Medicines Highlights Strong 12-Month Overall Survival Rate for Lead Cancer Drug Regimen
Revolution Medicines, Inc. (NASDAQ:RVMD) on Thursday reported encouraging updated results from its Phase 1/2 RMC-GI-102 open-label study of Rasonque (daraxonrasib) combined with gemcitabine and nab-paclitaxel (GnP) as a potential first-line treatment for metastatic pancreatic adenocarcinoma (PDAC) . The global, commercial-stage oncology company, which focuses on developing medicines for patients…
Revolution Medicines (RVMD) has released positive results from its Phase 1/2 RMC-GI-102 study on the combination of Rasonque (daraxonib) and gemcitabine/nab-paclitaxel as a potential first-line treatment for metastatic pancreatic adenocarcinoma (PDAC). The study, presented at the EORTC-NCI-AACR Symposium, showed a 76.6% 12-month overall survival rate in 61 patients who received the regimen, with a 60.7% objective response rate and a 90.2% disease control rate.
The safety profile of the combination therapy remained consistent with previous data for both Rasonque and gemcitabine/nab-paclitaxel.
Brief written by urgent.news from Benzinga's own syndicated text. Machine-written — may contain errors; check the original before relying on it.